August 18, 2026

Company name: TAUNS Laboratories, Inc.
Representative: Masaki Nonaka, President and CEO
(Code no.: 197A, Standard Market, Tokyo Stock Exchange)
Contact person: Yoshio Uchiyama, Director and CFO
Tel: +81-55-953-9590

Notice Concerning Craif's Series D Financing with TAUNS Laboratories as a Co-Lead Investor

TAUNS Laboratories, Inc. (headquartered in Izunokuni-shi, Shizuoka, Japan; Masaki Nonaka, President and CEO; Securities Code: 197A; hereinafter referred to as "TAUNS") hereby announces that Craif, Inc. (Head Office: Shinjuku-ku, Tokyo, Japan; CEO: Ryuichi Onose; hereinafter "Craif"), with which the Company has entered into a capital and business alliance, has completed its Series D financing round totaling approximately JPY 5.3 billion, with TAUNS Laboratories, Inc. and Granite Integral Capital Pte. Ltd. (headquartered in Singapore; Co-Founders and Managing Partners: CK Chuon and Joe Yan) serving as Co-Lead Investors. A portion of the total investment amount of JPY 5.3 billion has already been invested by TAUNS in advance.

1. Overview of the Financing

(1) Issuer	Craif, Inc.	
(2)Co-lead Investors	TAUNS Laboratories, Inc. Granite Integral Capital Pte. Ltd.	
(3) Total Amount Raised	Approximately JPY 5.3 billion Breakdown: Equity financing and secondary transactions: approximately JPY 4.8 billion Debt financing: JPY 0.5 billion	
(4) Investors and Lenders	①New Investors	Granite Integral Capital Pte. Ltd., Kodomonomori Co., Ltd., North Pacific Bank,Ltd., Other individual investors
	②Existing Investors	TAUNS Laboratories, Inc., X&KSK, Unreasonable Group, Nagase Future Investments Co., Ltd.
	③Lending Institutions	The Joyo Bank, Ltd., The Higashi-Nippon Bank, Limited, North Pacific Bank,Ltd., The Hokkoku Bank, Ltd., The Bank of Nagoya, Ltd., Japan Finance Corporation

2. Purpose of the Financing

The proceeds from this financing round will be used to strengthen Craif's R&D capabilities in the United States and support the launch of its products with a view toward achieving reimbursement coverage in the U.S. healthcare market.

In Japan, Craif will further expand the research and business development organizations supporting its urine-based cancer risk assessment service, miSignal®, while advancing clinical development activities aimed at obtaining regulatory approval for its pancreatic cancer Software as a Medical Device (SaMD) program.

Furthermore, leveraging the knowledge and data accumulated through these initiatives, Craif will accelerate the development of its "Urine Data Platform," which aims to enable the early detection of a broad range of diseases beyond cancer.

3. Relationship Between the Financing and the Company's Business

In July 2026, the Company entered into a business partnership agreement with Craif and obtained sales rights as one of Craif's distribution partners in Japan for miSignal Scan, to be marketed to medical institutions through pharmaceutical and medical device distributors.

In addition, the Company has obtained exclusive distribution rights in Japan for Craif's pancreatic cancer SaMD currently under development, for sales to medical institutions through the same distribution channel.

Furthermore, during the term of the business partnership agreement, the Company has been granted preferential negotiation rights with respect to SaMD products for other cancer types related to or derived from the pancreatic cancer SaMD, as well as future SaMD products to be commercialized by Craif.

The Company believes that this financing will contribute to the further enhancement of Craif's research, development, and business development capabilities, as well as the advancement of clinical development activities toward regulatory approval, thereby creating business synergies and accelerating initiatives arising from the partnership between the two companies.

4. Overview of Craif Inc.

(1) Name	Craif, Inc.
(2) Address	B1F THE PORTAL iidabashi, 8-30 Shin-ogawamachi, Shinjuku-ku, Tokyo 162-0814, Japan
(3) Title and name of representative	Ryuichi Onose, CEO
(4) Business	Research and development of next-generation diagnostic technologies, with a focus on early detection and personalized medicine for cancer and other diseases. Provider of miSignal® (available only in Japan), a non-invasive cancer risk testing service based on urinary microRNA analysis.
(5) Date of establishment	May 2018
(6) Relationship with the Company	Capital and Business Alliance Agreement (April 2025); Business Partnership Agreement (July 2026)
(7) Corporate site	https://craif.com/en

5. Comments from Both Companies

Comment from Masaki Nonaka, President and CEO of TAUNS Laboratories, Inc.

We are very pleased to participate as a Co-Lead Investor in Craif’s Series D financing round, and we view this investment as highly significant for our company.

Through this fundraising, we expect Craif to further strengthen its research and development capabilities and accelerate its global expansion. We are also confident that the pancreatic cancer Software as a Medical Device (SaMD) program currently under development, for which our company holds the exclusive commercialization rights in Japan, will make significant progress toward clinical development and broader adoption in healthcare practice.

Craif’s proprietary urinary microRNA analysis technology is an innovative platform with the potential to transform the early detection of cancer. Through our collaboration, we aim to make this technology available to a greater number of patients and healthcare providers.

We remain committed to supporting Craif’s long-term growth and advancing the commercialization of next-generation diagnostic technologies. Through these efforts, we will contribute to addressing critical healthcare challenges not only in Japan but also around the world.

Comment from Ryuichi Onose, CEO of Craif, Inc.

Since founding Craif in 2018, we have remained steadfast in our mission to solve the global challenge of cancer through innovations originating from Japan.

Today, our tests are available at more than 2,500 medical institutions across Japan, and we are approaching a major milestone with the regulatory submission of our pancreatic cancer program. At the same time, I have relocated to San Diego to lead our efforts on the front lines of the U.S. market.

What we are building goes beyond cancer diagnostics. Early biological signals of a wide range of diseases can be found in urine. The "Urine Data Platform" that analyzes these signals represents the essence of Craif's vision, while cancer is only our starting point.

We are pursuing this ambition in the world's most competitive healthcare market, the United States. Few Japanese startups have achieved major success in the U.S. healthcare industry. That is precisely why this challenge is worth taking on. To compete successfully, we need both an exceptional local team and the capital necessary to execute our vision. We regard this global financing round as a strong vote of confidence from investors around the world.

Every step of our journey, even those that seemed indirect, has contributed to the strength we have today. While continuing to accelerate our business in Japan, we will compete and win on the global stage. The real challenge begins now, and we are committed to shaping the future of healthcare with determination.

6. Outlook

At this time, the Company believes that the impact of the execution of this Agreement on its financial results will be immaterial. However, if it becomes apparent that the Agreement is expected to have a material impact on the Company's business performance, the Company will promptly disclose such information.

7. Other Matters

Certain details of this Agreement have not been disclosed in accordance with the mutual agreement of the parties.